Answers are grounded in this paper and cite their sources.
Purpose Type 2 diabetes mellitus (T2DM) increases the risk of sarcopenia, which independently contributes to bone fragility, especially among the elderly. Bone mineral content (BMC) is a parameter that helps in the assessment and monitoring of bone mass. This study aims to identify the correlation between BMC and sarcopenia in hospitalized patients with T2DM. Patients and methods A total of 1,135 inpatients admitted with T2DM in this study and classified into two groups (sarcopenia and non-sarcopenia group). A comparative analysis of clinical data and body composition was performed between the two groups. A multivariable logistic regression model was used to assess the independent association of BMC with sarcopenia. Results The sarcopenia group showed a lower BMC level than the non-sarcopenia group ( P < 0.001). The BMC level was correlated with a history of sarcopenia ( P < 0.001). The receiver operator characteristic (ROC) curve analysis showed a medium ability of BMC in predicting sarcopenia (area under the ROC curve=0.760). The optimal cut-off level for BMC to predict sarcopenia was found to be < 2.86 kg. Finally, in the multivariable logistic regression model, a BMC level < 2.86 kg was significantly associated with sarcopenia [odds ratio (OR) = 4.994, 95% confidence interval [CI] 3.130–7.967, P < 0.001]. Additional analyses revealed that lower BMC level was associated with an increased risk of sarcopenia irrespective of the subgroup of age (including elderly group and non-elderly group). Conclusion Our results confirmed that in hospitalized patients with T2DM, BMC levels are inversely associated with sarcopenia and may therefore serve as a biomarker for sarcopenia discrimination. But additional studies are needed to confirm and further elucidate our results.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: